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1. Introduction 
Treatment of various cells with hormones leads to 
a subsequent loss of responsiveness to the hormone, a 
phenomenon commonly denoted as 'desensitization'. 
Specific catecholamine-induced refractoriness, viz., 
'homologous desensitization' has been amply investi- 
gated [1-3] and was found to be associated with a 
net reduction of catecholamine-stimulated d nylate 
cyclase activity and with a net reduction in the num- 
ber of/3-adrenergic receptors. The observations in [4] 
strongly suggest that the agonist-specific desensitiza- 
tion in cultured astrocytoma cells initially occurs as a 
result of a rapid uncoupling of the ~-adrenergic recep- 
tor from the adenylate cyclase which is followed by 
the loss of the desensitized receptors. The contribu- 
tion of the uncoupling reaction to catecholamine- 
induced esensitization has also been reported with 
erythrocytes [5,6] and C6 glioma cells [7]. 
In vitro, exposure of the oestrogen-dominated rat 
myometrium to either a/~-adrenergic agonist or PGE2 
which enhanced intracellular cAMP generation [8,9] 
resulted in a subsequent refractory state of the tissue 
cAMP response to both stimuli [ 10]. The data revealed 
the existence of at least 2 distinct processes: a rapid 
event (5-10 min exposure), that results in a specific 
refractoriness to the inducing agent, and a non-specific 
process leading to a cross desensitization between iso- 
proterenol and PGE2, and vice versa, that can be 
detected only after prolonged exposure to the induc- 
ing agent, and that may involve cAMP as a mediator. 
Abbreviations: [3H]DHA, (-)[3H]dihydroalprenolol; Gpp- 
(NH)p, guanyl-5'-yl imidophosphate; MIX, 3-isobutyl-1- 
methylxanthine 
Here, the consequences of isoproterenol selective 
desensitization f the rat myometrium are analysed at 
the membrane/3-adrenergic receptor level. We show 
that the attenuated cAMP response to isoproterenol, 
when elicited by the agonist itself but not by PGE2, is 
associated with both a reduction in the number of 
/3-adrenergic binding sites, i.e., 'down regulation of 
receptors' and an impaired ability of the residual 
receptors to form a high affinity complex with the 
agonist, i.e. 'uncoupling process'. 
2. Experimental 
2.1. Chemicals and sources: 
(--)Alprenolol and (+)alprenolol tartrate (Hassle); 
(-)propranolol and (+)propranolol hydrochloride 
(Imperial Chemical Pharma); (-)isoproterenol and 
(+)isoproterenol bitartrate (Sigma); phentolamine 
mesylate (Ciba); (+)isoproterenol hydrochloride 
(Fluka AG); Gpp(NH)p (Boehringer); PGE2 (gift 
from Dr J. E. Pike, Upjohn Co.); (-)-[3H]dihydroal- 
prenolol (42 Ci/mmol) (New England Nuclear). 
2.2. Animals and tissue processing 
Uteri were obtained from oestrogen-pretreated rats 
(Wistar, 4-5 weeks old) and myometrium was pre- 
pared free of endometrium [8,t0]. Myometrial strips 
(~50 mg) were routinely allowed to equilibrate in 
2.0 ml Krebs bicarbonate buffer, containing 10 mM 
glucose for 25 min at 37°C (gas phase, 95% O2 plus 
5% CO2) under continuous agitation and subsequently 
used for membrane preparation or further incubated 
for the different desensitization treatments. 
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2.3. Preparation of crude membrane fractions 
Myometrial strips were homogenized with an 
Ultra-Turrax homogenizer in 10 vol. cold buffer con- 
sisting of 0.25 M sucrose, 1 mM MgC12, 5 mM Tris 
HC1 (pH 7.4) and centrifuged at 700 X g for 5 rain. 
The sediment was washed by resuspension i  the 
buffer and centrifugation at700 × g. The pooled 
700 X g supernatant fractions were centrifuged at 
100 000 X g for 1 h. The resulting pellet was sus- 
pended in cold 50 mM Tris-HCl buffer (pH 7.4), 
10 mM MgCI2 at 4 mg protein/ml final conc. [11]. 
2.4. Binding assay of/3H/DHA 
Membrane proteins (~0.4 mg) were incubated 
with the indicated concentrations of [31t] DHA 
(1-15 nM) for 15 min at 30°C in 50 ntM Tris-HC1 
(pH 7.4), 10 mM MgC12, in 400 #1 final vol. When 
present, Gpp(NH)p was at 100/JM. At the end of the 
incubation, triplicate 100/Jl aliquots were diluted 
with 4 ml ice-cold buffer and immediately filtered 
through Whatman GF/C glass fiber filters under 
reduced pressure. Filters were washed 3 times with 
5 ml cold buffer, dried and the bound radioactivity 
determined by scintillation counting. Specific binding 
was defined as the difference between the amount of 
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[3H] DHA bound in the absence (total binding) and 
the presence (non-specific binding)of 10/aM unlabeled 
propranolol. In all results, bound [3HI DHA refers 
only to specific binding which approximated 80% and 
90% of the total binding, for 15 nM and 3 nM of 
tracer, respectively. 
2.5. Desensitization treatment 
Following the 25 rain equilibration period, incuba- 
tion of myometrimn strips in Krebs buffer at 37°C 
was further continued with or without he addition 
of the indicated agonist for various tinres depending 
on the experiment. The tissue strips were subsequently 
washed 3 times with 10 1111 hormone-free buffer, 
transferred to 2.0 ml fresh buffer, and allowed to 
equilibrate 5 rain at 37°C before the preparation of 
particulate fractions for [3tf] DHA binding assay. 
2.6. Assay of cAMP levels 
In some experiments, the above-treated tissues 
were rechallenged with 0.3/aM isoproterenol in the 
presence of 275 ~tM MIX for estimation of cAMP 
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Fig. 1. Specific binding of [ 31-t] DHA to myometrial  membranes as a function of [ 3H 1DHA concentration. (A) Membranes (1 mg/ 
ml) prepared from control (o) and from myometrial  strips pre-treated for 1 h with 10 uM isoproterenol (a) were incubated with 
the indicated concentrations of [ 3H]DHA and specific binding was determined as in section 2. Each value is the mean of triplicate 
determinations. (B) Scatchard plot of [3HI DIIA binding to membranes from control (o) and prc-treated myometr ium (zx). The 
intercept on the abscissa is equal to the maximal binding capacity (Bmax) and the slope is equal to I/K d. 
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3. Results and discussion 
3.1. Characteristics of( }[ 3H]DHA binding in 
particulate fractions of rat myometrium 
The presence of 13-adrenergic receptors on 
oestrogen-pretreated rat myometrial membranes had 
been demonstrated by the ability of catecholamines 
to induce relaxation and intracellular cAMP accumu- 
lation [8]. Here, 15-adrenergic receptors were directly 
monitored in the particulate fractions by binding of 
the radiolabeled antagonist [3H] DHA. As shown in 
fig. 1, the specific binding of [ 3H] DHA was a saturable 
process. The equilibrium dissociation constant (Kd) 
determined by Scatchard analysis was found equal to 
0.9 -+ 0.1 riM. One class of binding sites was character- 
ized with a maximal number of 200 + 12 fmol 
[3H] DHA bound/nag of membrane protein. Specific 
binding of [3HI DHA to the particulate fraction 
reached equilibrium within 5 rain at 37°C and was 
rapidly reversible: 80% of bound [3H] DHA was dis- 
sociated within 5 rain after addition of unlabeled 
alprenolol. Dissociation experiments (not shown) 
revealed no discrepancy between isotopic dilution 
and isotopic + chemical dilutions which agrees with 
the absence of cooperativity between binding sites. In 
the presence of 3 nM [3HI DHA, specific binding was 
linear with membrane protein at 0 .3-2 mg/ml. 
The identity of [3H] DHA binding sites with 
t3-adrenergic receptors was confirmed by competition 
binding experiments (fig.2). The ~-adrenergic agonist, 
(-)-isoproterenol and antagonists (-)-propranolol 
and (-)-alprenolol caused a complete and dose-depen- 
dent decrease of [3H] DHA binding with a respective 
apparent dissociation constant 'K d' of 0.11 taM, 
0.0017 tam and 0.0008 taM (calculations were made 
according to [12] from the concentrations causing 
50% decrease of [3H] DHA binding). The a-adrenergic 
antagonist phentolamine, was ineffective in competing 
for the binding sites. 
A fundamental property of the ~-adrenergic ago- 
nists, not shared by antagonists, is the ability to allow 
formation of a high affinity state of t3-adrenergic 
receptor which is shifted to a lower affinity state in 
the presence of guanyl nucleotides. In contrast, antag- 
onist binding to the receptor is characterized by a 
single affinity form insensitive to guanyl nucleotides. 
The 'shift' from the high to the low affinity form of 
the agonist-receptor complex is normally associated 
with an increase in the agonist induced adenylate 
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Fig.2. Displacement ofbound [ 3tt]DHA by adrenergic agents 
in myometrial membranes: effect of Gpp(NH)p. Membrane 
preparations were incubated with 3 nM [aH]DHA and vari- 
ous concentrations of (-)isoproterenol, (-)alprenolol 
(-)propranolol and ( )phentolamine, in the absence ( - - )  
or presence (...) of 100 #M Gpp(NH)p. Results are expressed 
as the percentage of the specific [3H]DHA binding in the 
absence of any competing agent (170 fmol/mg protein). 
Experimental points axe the mean of 2-6 different determi- 
nations. 
different 'uncoupled systems', the receptor displays a 
uniform low affinity for the agonist which is not 
affected by guanylnucleotides [13-17].  Data of fig.2 
illustrate that the t3-adrenergic receptors of the rat 
myometrium exhibit binding characteristics of 'cou- 
pled receptors'. The displacement curve of isopro- 
terenol for [ 3H] DHA binding is indeed shifted to the 
right when binding was assayed in the presence of 
100 taM GppNHp with a 5-fold reduction in the ago- 
nist affinity (K d for isoproterenol 0.11 + 0.01 and 
0.5 + 0.07 taM, p < 0.05, in the absence and presence 
of guanylnucleotide, r spectively). Under similar con- 
ditions, the displacement curve for propranolol was 
not altered by Gpp(NH)p. Similar binding properties 
have been described for the t3-adrenergic receptors in 
the adult rat uterus at different stages of the oestrus 
cycle [ 18]. 
3.2. Modulation in the number and properties of 
(3-adrenergic receptors in desensitized 
myometrium 
Exposure of myometrial strips to isoproterenol 
leads to a subsequent decrease in the 15-adrenergic 
response in terms of cAMP [10]. Data of fig.1 illus- 
trate that this phenomenon is also accompanied by a 
reduction in the number oft3-adrenergic receptors in 
the membranes. The total number of [3HI DHA 
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binding sites in the membranes prepared from tissue 
exposed to isoproterenol, 10/~M, 1 h at 37°C, repre- 
sent only 70% of the initial number of binding sites in 
control membranes. Scatchard analysis of the data 
indicated that the K d of [3HI DHA for binding to 
control (0.9 + 0.1 nM) and desensitized (1.1 + 0.15 nM) 
membranes are virtually identical. The time courses 
of/3-adrenergic cAMP response and of~-adrenergic 
receptor losses appear to be similar (fig.3). Both 
phenomena were already detectable within 10 min 
exposure to the agonist and reached a plateau value 
after 30-45  min pretreatment. Total [3HI DHA 
binding sites in desensitized membranes averaged 
140 -+ 10 vs 200 + 12 flnol/mg protein for control 
(p < 0.05). Of importance was the observation that 
the extent of/3-adrenergic receptor losses was consis- 
tently lower than the decline in the isoproterenol 
response in terms of cAMP. No further decrease in 
the number of/3-adrenergic receptors could be 
obtained by prolongation of pretreatment of the 
myometrium with isoproterenol. 
Performing binding assays in the presence of 100 #M 
Gpp(NH)p had no effect on the apparent number of 
[all] DHA binding sites in membranes of desensitized 
myometrium. In contrast o the substantial restora- 
tion of [3H] DHA binding sites in the presence of 
guanyl nucleotides in membranes from isoproterenol 
desensitized myometrium [19], the degree of [3H]- 
DHA binding loss in the present study was identical 
under all assay conditions. Our results clearly indicate 
that residually bound agonist cannot account for the 
reduction in the binding capacity caused by incuba- 
tion of the intact myometrium with isoproterenol. 
Indeed, Gpp(NH)p which lowers agonist affinity 
(fig.2) should have led to rapid dissociation of the 
agonist from the receptors [1]. The phenomenon 
(fig.3) is rather consistent with a down regulation of 
13-adrenergic receptors in the desensitized myo- 
metrium. As also shown in fig.3, prior treatment of 
the myometrium with PGEa, under conditions where 
the subsequent responsiveness to isoproterenol was 
markedly attenuated, resulted in no change in the 
density of ¢/-adrenergic receptors (p < 0.4). 
Fig.4 illustrates the agonist binding properties of 
~-adrenergic receptors for control and post-desensi- 
tized membrane fractions. Following tissue incubation 
with isoproterenol (10 ~M, 1 h), concomitant to the 
loss of [3H] DHA binding sites (30%), the ability of 
the residual membrane receptors to form a high affin- 
ity state seems to be impaired (fig.4A). The latter 
observation is consistent with the notion of uncou- 
pling between the receptor and the nucleotide regula- 
tory component [4,5,15]. That is, in the absence of 
Gpp(NH)p, the K d for isoproterenol determined in
competition binding studies with membranes from 
the desensitized tissue (0.3 -+ 0.03/JM), is shifted to 
values 3-4-fold greater than that observed in control 
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Fig.3. Time courses of decrease in ¢~-adrenergic e eptor den- 
sity and isoproterenol-stimulated cAMP accumulation during 
incubation of rat myometrium with isoproterenol orPGE 2. 
Tissues were incubated with 10 uM isoproterenol (a,A) or 
30 #M PGE 2 (e). At the indicated times, tissues were washed 
free of hormone and used (A) for membrane preparation and 
binding assay with 15 nM [aH]DHA in the absence (zx) or 
presence (A) of 100/aM Gpp(NH)p or (B) for rechallenge 
incubations with 0.3 uM isoproterenol before cAMP determi- 
nations as in section 2. For control tissue specific [ 3H]DHA 
binding was 198 -+ 15 flnol/mg protein and cAMP response to 
isoproterenol was 102 +_ 10 pmol cAMP/rag protein. Results 
are expressed as the percentage of control binding (A) and 
control cAMP response (B). Values represent the mean + SE 
of 4-6 expt. 
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Fig.4. Concentration effect curves for inhibition of [3H] DHA binding by (-)isoproterenol in membrane preparations from con- 
trol, desensitized and resensitized tissues. Myometrial strips were incubated in the absence (o,e) or presence (zx,A) of 10 pM iso- 
proterenol for 1 h (A), 5 min (B) or in the presence (~,-) of 30 ~zM PGE~ (D). Tissues were then washed free of hormone and 
membrane fractions prepared as in section 2. Binding assays were carried out with 3 nM[ 3H] DHA in the absence (open symbols) 
and presence (closed symbols) of 100 pM Gpp(NH)p. For (C) tissues were incubated 1h with 10/~M isoproterenol washed as 
above and subsequently incubated in 5 ml hormone-free buffer for 90 min prior to preparation of membranes, and assay of 
[ 3H] DHA binding in the absence (z~) and presence (A) of 100 pM Gpp(NH)p. Data are expressed as percent of maximal specific 
binding (which averaged: (A) control 165 -* 15, desensitized 110 -+ 10; (B) 118 +- 12; (C) 112 _+ 12; (D) 160 _+ 10 fmol [3H]DHA 
bound/mg membrane protein). Values represent the pooled means from 3-6 similar expt. 
proterenol in the presence of Gpp(NH)p is similar for 
control and desensitized membranes. As a result, 
Gpp(NH)p effects a smaller eduction (1.6-fold) in 
the apparent affinity for isoproterenol than that 
observed for receptors in membranes of control cells 
(4-5-fold) (fig.3,4). Fig.4B shows that the impairment 
in the ability of the receptor to form a high affinity 
state is already detectable following 5 rain incubation 
with isoproterenol but the effect on the degree of 
uncoupling was less pronounced. In the latter case the 
K d for isoproterenol was shifted to a value of 0.22 + 
0.04 #M (significantly different from control, 
p < 0.01), with a 2.2-fold reduction in the K d in the 
presence of Gpp(NH)p. In contrast, he agonist binding 
properties to the/3-adrenergic receptor in membranes 
derived from myometrium pretreated with PGE2 
(10/aM, 1 h) were undistinguishable from those of 
control tissue (fig.4D). 
Fig.5 and 4C demonstrate he ability of the myo- 
metrium to recover following isoproterenol induced 
desensitization. On washing myometrial preparations 
pre-treated with 10/aM isoproterenol for 1 h and 
further incubated in a hormone-free medium, a time- 
lag preceded the onset of recovery of isoproteren.ol 
responsiveness in terms of cAMP accumulation, in 
agreement with [10]. Nevertheless, loss of membrane 
receptors was still not recovered after 2 h incubation 
of intact tissue in the absence of the agonist, under 
35 







J ! '  
. . . .  | I I I I 
0 30 60 90 120 
Time (min) 
Fig.5. Time required for recovery of isoproterenol-induced 
refractoriness. Myometrial strips were initially exposed to 
10/2M isoproterenol f r 60 min as shown by the dotted line 
on the abscissa. The agonist was then removed by 3 succes- 
sive washings. Tissues were subsequently incubated in hor- 
mone-free buffer and at the indicated times used for mem- 
brane preparation and binding assay with 15 nM [3H]DHA 
(A) or for rechallenge incubations with 0.3 **M isoproterenol 
and cAMP determinations (o). The response of the treated 
tissue is expressed as the percent of the response of control 
tissue treated the same but without isoproterenol in the 
60 min exposure period. Control values were 210 + 15 fmol 
[ 3H]DHA bound/mg membrane protein and 120 -+ 12 pmol 
cAMP/mg protein in response to isoproterenol. Values repre- 
sent the mean ± SE of 3 expt. 
conditions where 40-50% of the ability of isopro- 
terenol to stimulate cAMP accumulation was already 
restored (fig.5). Of interest was the observation that 
in this situation, the uncoupling phenomenon at the 
level of/3-adrenergic receptors was substantially 
reduced (fig.4C). The membrane receptors restored 
their ability to form a high affinity state as well as 
their sensitivity to shift to a low affinity state in the 
presence of Gpp(NH)p. In the resensitized membrane 
K d for isoproterenol in the absence and presence of 
the guanyl nucleotide (0.1 + 0.01 and 0.45 + 0.05 #M, 
respectively) were close to those of control tissues. 
Thus the recovery of normal agonist binding proper- 
ties coincides with the progressive restoration of iso- 
proterenol stimulated cAMP accumulation i the 
myometrium. 
In conclusion, these findings imply that for the 
oestrogen-treated rat myolnetrium, the isoproterenol- 
induced self-refractoriness in terms of the cAMP 
response may readily be explained by both a reduction 
in the number of membrane receptors and the uncou- 
pling process at the level of residual ~3-adrenergic 
receptors. Thus the percent loss in cAMP response to 
isoproterenol can reasonably be expected to exceed 
the percent loss of total receptor populations as lnea- 
sured by [3H] DHA binding. It must be emphasized 
that the relation of the loss ofl3-adrenergic receptors 
to the uncoupling reaction is not entirely clear [4,5,7]. 
Nonetheless, if the time courses of development of
refractoriness in the myometrium did not allow one 
to distinguish temporally, uncoupling from receptor 
losses, the kinetics of the reversibility process clearly 
demonstrate that the apparent conversion of 'uncou- 
pled' to 'coupled' receptor is rapid compared to the 
recovery of lost receptors. Here, the restoration of 
normal receptor density following myometrium 
refractoriness has not been thoroughly investigated 
but appeared, as emphasized for other systems [3,4], 
a very slow process that may readily explain the 
incomplete recovery of cAMP response to isopro- 
terenol even 4 h after removal of the agonist [10]. 
Finally, it is clear that both the uncoupling and the 
down regulation phenomena can solely and specifically 
be promoted by the agonist itself and do not seem 
apparently to be mediated by cAMP. Elevation of 
cAMP content of the myometrium by PGE2 did not 
affect the level nor the agonist binding properties of 
the/3-adrenergic receptors. These data support our 
interpretation [10] that a distinct mechanism is
involved in the cross-desensitization caused by PGE2 
towards isoproterenol-cAMP response in the intact 
myometrium. The latter mechanism, as suggested by 
these observations, should be operating at a step distal 
to the membrane/3-adrenergic eceptors. 
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